Ulcerative colitis is a chronic inflammatory bowel disease marked by ulceration, bleeding, abdominal pain, diarrhea, and recurrent periods of flare and remission. Treatment with biologics and targeted small molecules has improved clinical care, but substantial residual pathology often persists in patients with mild-to-moderate disease. Earlier animal experiments have linked a multi-mineral product derived from calcified red marine algae to reduced gastrointestinal inflammation and fewer neoplastic lesions, while organoid studies using human colon tissue had shown increased expression of proteins involved in gut barrier structure and reduced expression of proteins associated with pro-inflammatory signaling. A prior biomarker study in healthy adults moved this question one step closer to the clinic, demonstrating that some of these same tissue-level protein shifts could also be detected in human colonic biopsies after oral intake. Importantly, ulcerative colitis also carries consequences beyond the colon. If chronic bowel disease changes inflammation, absorption, and mucosal physiology over prolonged periods, then a mineral-based intervention might affect more than one disease-related axis simultaneously. In a recent research paper published in PLoS One, Muhammad Aslam and colleagues (Danielle Kim Turgeon, Henry Appelman, Ryan Stidham, Shannon McClintock, Ron Allen, Gillian Moraga, Isabelle Harber, Kara Jencks, Molly McNeely, Ananda Sen, Karl Jepsen, and James Varani) at the University of Michigan Medical School designed a randomized 180-day biomarker trial, pairing a marine red algae-derived multi-mineral intervention with serial blood, stool, colon biopsy, mucosal proteomics, and Dual-energy X-ray absorptiometry (DEXA) measurements in ulcerative colitis patients before and after the intervention.     

Briefly, the investigators ran a single-site, double-blind, randomized, placebo-controlled crossover trial in 28 participants with UC in remission or with mild disease. They assigned 12 participants to Aquamin for the full 180 days and 16 participants to placebo for 90 days, followed by crossover to Aquamin for the final 90 days, while all participants continued their usual maintenance therapy. The team collected blood, stool, and sigmoid biopsies at baseline, day 90, and day 180, and included DEXA imaging at baseline and day 180 to capture skeletal effects that shorter intervals would likely miss. Their design recognized that barrier biology, inflammatory activity, and bone remodeling do not move on the same timescale. The research team measured serum chemistry markers, C-reactive protein, intestine-specific alkaline phosphatase, fecal calprotectin, histologic injury, bone turnover markers, and mucosal proteomic profiles. They found little change across the standard safety chemistry panel apart from alkaline phosphatase, which fell by 9% after 180 days of Aquamin and rose slightly in the placebo group. They then separated the intestine-specific isoform and found the same directional split: ALPI decreased by 10% with Aquamin over 180 days and increased by 17% with placebo. The investigators also tracked inflammatory burden through CRP and fecal calprotectin. CRP declined by 24% in the 180-day Aquamin arm while the placebo group showed a small increase, and fecal calprotectin dropped by 29.4% with prolonged Aquamin exposure while rising by 43% under placebo. The pathologist recorded low baseline scores in most biopsies, which fits the mild-disease population, but Aquamin still shifted the simplified Geboes score downward by 48%, whereas placebo pushed it upward by 121%. When the authors combined these five biomarker changes into a composite measure, they achieved statistical significance between the groups.

In parallel, the researchers profiled mucosal biopsies using mass spectrometry-based proteomics and focused on proteins linked to epithelial differentiation, barrier assembly, inflammation, and electrolyte transport. They found increased expression of keratins and filamin; mucus-layer proteins such as MUC2, FCGBP and ZG16; tight-junction-associated proteins including TJP1 and JAM-A; multiple cadherins (including CDH1 and CDH17); and desmosomal proteins (DSC2, DSG2, and DSP). They also identified higher expression of EPCAM, CHL1, and basement-membrane components, consistent with tissue shifting toward stronger epithelial organization. At the same time, the investigators observed reduced levels of proteins tied to inflammatory drive or neutrophil activity, including PLA2G2A, JAK1, lactotransferrin, and NCF1, while proteins associated with counter-inflammatory control or mucosal homeostasis, including SMAD4, PIGR, MEP1A, tissue ALPI, and several carbonic anhydrase isoenzymes, moved upward. They also noted upregulation of transport-related proteins, including Na⁺/K⁺-ATPase subunits (ATP1B1 and ATP1B3); CLCA1/4 and CLIC5, and multiple SLC family members including SLC26A3 (also known as DRA).

Lastly, the study team also examined bone outcomes in parallel with the intestinal biomarkers. The authors measured femoral neck and lumbar spine parameters by DEXA and paired those readouts with serum bone turnover markers such as osteocalcin, TRAP5b, and bone-specific alkaline phosphatase (BALP). After 180 days of Aquamin intake, they observed a 1% increase in femoral neck bone mineral density (BMD) and a 3% increase in bone mineral content (BMC), contributing to a 7% gain in the calculated hip strength index. This is notable because, with many pharmaceutical interventions, achieving comparable improvements in BMD and BMC often takes a couple of years. The investigators then found a matching bone remodeling pattern in serum: osteocalcin rose by 34%, TRAP5b rose by 22%, and BALP fell by 9%, while placebo moved in the opposite direction or showed little change. Bone turnover is rarely captured through one perfectly synchronized marker, and the authors addressed that complexity by comparing the composite behavior of the marker set instead of over-interpreting any one analyte.

To summarize, the study by Muhammad Aslam and colleagues showed improvement in several biomarkers under the mineral intervention, and the proteomic results, the shifts in fecal calprotectin and histology, and the movement in intestine-linked alkaline phosphatase converge on a more layered interpretation: mucosal stability may change when epithelial architecture, mucus production, tight-junction support, and ion transport move in a coordinated direction. Drug development for ulcerative colitis usually focuses on stronger immune suppression or more selective cytokine control. However, the intervention seems to work by altering the mucosal setting in which inflammation persists, and this reflects a different therapeutic logic. If future trials confirm these observations, one could imagine mineral-based support entering maintenance strategies not as a replacement for established treatment, but as a means of shifting the tissue environment away from chronic fragility. In a cohort without dramatic baseline inflammation, the biomarker shifts still support a meaningful biological signal. The authors’ bone findings extend the relevance of the study beyond intestinal inflammation alone. Ulcerative colitis-associated bone loss is usually treated as a complication to monitor, not as a process linked back to the same intervention being tested for intestinal health. Aquamin shifted femoral neck mineral accrual, hip strength index, and bone turnover markers in a direction consistent with active remodeling and improved structural status over six months. Still, the findings raise a practical possibility: a well-tolerated adjunct that affects both mucosal biomarkers and skeletal endpoints could be especially relevant for patients whose disease remains clinically quiescent while extraintestinal burdens accumulate slowly over years. Barrier repair is one important theme in ulcerative colitis, and fluid absorption and electrolyte handling also shape bowel function in direct ways. When the authors report increased expression of SLC26A3 and ATPase subunits involved in ion gradients, they open a second mechanistic path for symptom benefit which may be considered less dramatic or complex than cytokine biology, though perhaps closer to how patients feel from day to day. If later trials connect these transporter changes to stool pattern or urgency, the medical field may need to rethink mucosal physiology as an attractive treatment target, not just inflammation biomarkers.

Necrotic myocardium does not fail in a single way after coronary occlusion. Cardiomyocyte death initiates inflammation, matrix remodelling, vascular responses, and fibroblast activation all at once, however, bulk tissue measurements flatten those events into averages and obscure the cells that may decide whether the ventricle scars, stabilizes, or partially recovers.  The scientific question is not simply which cells appear after myocardial infarction, but which chromatin programs become accessible as repair unfolds, and how those programs relate to cell fate. Fibroblasts have long been thought of as central executors of scar formation, but their behaviour during repair remains not fully understood. They are heterogeneous, temporally plastic, and exposed to a damaged environment that can push them toward matrix deposition, mechanical support, or lineage-adjacent states that are harder to classify. Transcript data alone can register gene expression, but it cannot fully reveal the regulatory architecture that permits one fibroblast population to remain fibrotic while another moves toward a more developmentally charged identity.  In a recent research paper published in Cardiovascular Research, Dr. Shuchen Zhang, Dr.  Boyang Xiang, Dr.  Yiheng Zhao, and led by Professor Xiang Zhou from the Second Affiliated Hospital of Nanjing Medical University working together with Dr. Wenjing Wang and Dr. Lili Chen from the Second Affiliated Hospital of Soochow University, examined cardiac repair after myocardial infarction using integrated single-cell epigenomic and transcriptomic analysis. Their work resolved regulatory fibroblast states that are not easily captured by transcript profiling alone. They identified a GATA5/ISL1+ fibroblast population with mixed fibroblast and cardiomyocyte features, distinct from transient Gli3 high fibroblasts and from conventional myofibroblasts. They also built a fibroblast-targeted adenoviral overexpression strategy and connected its repair-associated effects to repression of the Rspo1–β-catenin–TCF4 arm of Wnt signalling in mouse and human cardiac fibroblasts.

This is why the authors combined scATAC-seq with scRNA-seq in mouse hearts collected across the early and intermediate phases after left anterior descending coronary ligation, and why they extended the logic of the study into human post-infarct tissue. The design carries a clear intellectual motive. Myocardial repair is not static, and any attempt to understand it without temporal resolution risks confusing transient intermediates with stable cell types. The same issue applies to fibroblasts: a population identified late after infarction may have emerged through several short-lived states that leave regulatory traces even when the transcriptional signal has already shifted. By linking chromatin accessibility to gene activity and transferred RNA labels, the investigators placed cell identity and regulatory potential into the same analytical frame.   If fibroblast behaviour is controlled by a sequence of regulatory openings and closures, then the path into repair becomes as important as the final scar itself.

The research team generated scATAC-seq profiles from control hearts and from infarcted hearts sampled at 1, 3, 7, and 14 days, then integrated those data with reference scRNA-seq to annotate cell states across more than 40,000 cells. They identified the expected endothelial, mural, immune, lymphoid, and fibroblast populations, yet the analysis also separated two fibroblast groups that had not been resolved in the prior transcript-only framework: a Gli3high population and a GATA5/ISL1+ population. The investigators observed immediate monocyte/macrophage expansion after infarction, peaking early and subsiding by day 14, while fibroblasts followed a different rhythm, shrinking at day 1 under the weight of inflammatory influx and then expanding through later repair.  

The authors then focused on fibroblast lineage structure. They found that activated fibroblasts rose as Sca1-high and Sca1-low fibroblasts declined, while myofibroblasts surged early and then receded. Gli3high fibroblasts appeared briefly and carried a chromatin program close to myofibroblasts, which led the investigators to treat them as a transitional state. GATA5/ISL1+ fibroblasts behaved differently. Their abundance increased from day 3, plateaued by day 7, and still accounted for about one-fifth of fibroblasts at day 14, outlasting both myofibroblasts and Gli3high cells. The researchers linked this population to mesenchymal development, heart morphogenesis, actin filament organization, and mesenchymal differentiation, and they found chromatin and motif similarity to both myofibroblasts and cardiomyocytes. That mixed signature is scientifically interesting because it does not fit the usual binary choice of fibrotic versus muscle. It reads more like a repair state under developmental pressure, still tethered to fibroblast identity but no longer confined by it.

The study examined mechanism and function in parallel. They connected GATA5 occupancy with downstream target gene scores, and immunostaining confirmed the appearance of GATA5/ISL1+ fibroblasts in infarcted tissue. The investigators also detected cardiac transcription factors and muscle-associated genes in these cells, which strengthened the argument that they had acquired part of a cardiomyocyte-like program. To test whether this state could influence repair, the authors drove GATA5 and ISL1 expression in cardiac fibroblasts using an adenoviral system built around a collagen promoter. They observed improved ventricular function trends, less fibrosis, smaller infarcts, and enrichment of GATA5/ISL1+ fibroblasts in the infarct border zone. Forced expression helps clarify the biological axis, while the endogenous programme likely follows a more context-dependent course. Even so, the concordance between the endogenous single-cell data and the intervention data gives the argument unusual weight. RNA-seq and protein analysis then pulled the mechanism toward Wnt control, with reduced Rspo1, β-catenin, and TCF4 accompanying GATA5/ISL1 expression. Human scar tissue contained GATA5/ISL1+ fibroblasts as well, and proteomics in human cardiac fibroblasts linked the same axis to cardiac development, homeostasis, angiogenesis, matrix regulation, and fatty acid oxidation.

What makes this paper matter is that it shifts the conversation about post-infarct fibroblasts away from a single-path scar narrative. Fibroblasts in the injured heart are often discussed as drivers of collagen deposition, mechanical stabilization, and later stiffness, all of which are true. Professor Xiang Zhou and colleagues demonstrated that at least one fibroblast state carries a regulatory program closer to tissue reconstitution than to terminal fibrosis. That does not mean the infarcted heart is naturally regenerating in any broad sense. It means the repair field may contain a narrower, temporally restricted cell population whose chromatin state permits partial movement toward a cardiomyocyte-like transcriptional identity. It opens the door to design principles based on timing, transcription factor combinations, and cell-state conversion, instead of the familiar attempt to suppress fibroblast activity wholesale.

By merging chromatin accessibility with transcript data, the authors show that repair biology after myocardial infarction cannot be fully understood from expression matrices alone. Regulatory potential leaves a signal before terminal phenotype becomes obvious, and transient intermediates may be visible in one modality more clearly than the other. The identification of Gli3high fibroblasts as a short-lived state and GATA5/ISL1+ fibroblasts as a later, more persistent state illustrates that point well. For cardiac biology, this matters because repair is a staged process; a cell that appears only briefly may still determine what comes next. For therapeutic thinking, the novel work implies that interventions aimed at fibroblasts may need to discriminate among fibroblast states with much finer temporal resolution than current anti-fibrotic strategies usually allow. A program that is beneficial in the border zone during one repair window could easily be lost, or misread as noise, in coarser analyses. The translational implications are promising and the appearance of the same fibroblast state in human scar tissue gives the study a confirmation beyond rodent inference. The Wnt-associated regulatory axis is equally important. If GATA5/ISL1-dependent suppression of the Rspo1–β-catenin–TCF4 arm of Wnt signalling marks a route by which fibroblasts loosen their fibrotic program and acquire cardiac features, then future work could treat that axis as a target for selective reprogramming, provided cell targeting and timing can be handled with precision.  

When caloric intake stays high for long enough, adipose tissue and liver begin to accumulate triglycerides at higher normal turnover, but the molecular controls that allow this to happen are not evenly distributed across regulatory layers.  A fair amount of lipid handling seems to hinge on whether certain protein modifications can be written and erased as metabolic conditions shift. Acetylation and deacetylation fit neatly into this picture, given their tight dependence on acetyl-CoA. Nitric oxide–linked modifications   appear everywhere, affect enzymes and the cytoskeleton alike, yet they still sit awkwardly in most metabolic models. De novo lipogenesis channels excess carbon into fatty acids through a small set of enzymes that have to operate within narrow bounds and push hard toward synthesis and oxidation suffers; pull back too far and storage collapses. In adipocytes, this balance determines whether cells enlarge and retain triglycerides. In hepatocytes, it influences steatosis and downstream stress responses. Transcription factors such as PPARγ, SREBP1, and CEBP family members organize the expression of the relevant enzymes, but their activity is not autonomous. It depends on what the cell can physically and chemically accommodate. Changes in actin organization, contractile tone, or even protein solubility can tip lipogenic programs toward continuation or failure and this kind of coupling makes simple regulatory diagrams feel incomplete. S-nitrosylation offers a way to think about this coupling. The modification is reversible and capable of altering both catalytic activity and cytoskeletal behavior. Its persistence seems to depend less on how much nitric oxide is produced than on how efficiently it is removed, which puts denitrosylases in a position to control signal duration. Enzymes in the SCoR family carry out this removal using coenzyme A, but their biological role has resisted a single explanation. Studies in yeast, zebrafish, and mammals have identified very different targets. It is still unclear whether these enzymes enforce a common metabolic logic or simply respond to local context.  Obesity and metabolic dysfunction–associated steatotic liver disease highlight the limits of models that focus on intake and expenditure while paying less attention to intracellular erasure mechanisms. Human genetic links between regulatory enzymes and body mass suggest that these layers may bias lipid fate well before disease becomes obvious. What remains missing is a clear mechanistic bridge connecting denitrosylation, transcriptional control, and tissue-specific lipid flux.

A recent research paper published in Cell Signaling and conducted by Dr. Nicholas Venetos, Dr.  Colin Stomberski, Dr.  Hua-Lin Zhou, Zhaoxia Qian, Dr.  Precious McLaughlin, Puneet Bansal, John Feczko, Ilya Bederman, Dr.  Hoa Nguyen, Dr. Alfred Hausladen, Joseph Schindler, Zachary Grimmett, Henri Brunengraber, Dr. Richard Premont, and led by Professor Jonathan Stamler from the Case Western Reserve University, the authors developed a mechanistic framework linking SCoR2-dependent denitrosylation to lipid synthesis control in adipocytes and hepatocytes. They identified Myh9 as a cytoskeletal target that limits adipogenic transcription when S-nitrosylated and ACLY and FASN as hepatic enzyme targets with reduced activity under the same modification. The work distinguishes tissue-specific substrates under a shared chemical control process.

The research team examined human genetic data and identified a promoter variant associated with increased body mass that elevated transcriptional activity of the denitrosylase SCoR2. The investigators correlated SCoR2 abundance with adipocyte size in human tissue and with weight gain in mice, establishing a link between enzyme level and lipid storage capacity. To test necessity, the authors challenged SCoR2-deficient mice with obesogenic diets and observed resistance to weight gain without changes in food intake or absorption, directing attention away from behavior and toward intracellular synthesis. The researchers assessed adipose tissue directly and found reduced fat pad mass and smaller adipocytes across diets, prompting a focused analysis of lipid synthesis. Measurements of lipolysis failed to differ between genotypes, narrowing the explanation to synthetic pathways. Using primary cells and 3T3-L1 models, the study demonstrated impaired adipocyte differentiation and reduced neutral lipid accumulation when SCoR2 activity was absent, accompanied by blunted induction of CEBPβ and later suppression of PPARγ and CEBPα.

The authors interrogated transcriptional control more deeply and observed defective processing of SREBP1 without changes in its precursor abundance or transcript level. This separation between synthesis and activation suggested interference at a structural checkpoint. Proteomic screening identified the actomyosin regulator Myh9 as a prominent SCoR2-associated protein, and the researchers showed increased S-nitrosylation of Myh9 when SCoR2 was removed. Functional assays revealed enhanced actin polymerization and contractile assembly under these conditions, linking chemical modification to mechanical constraint. To establish causality, the investigators mutated specific cysteine residues on Myh9 and demonstrated resistance to nitric oxide–induced assembly when S-nitrosylation sites were removed. Reconstitution experiments restored transcription factor accumulation, tying cytoskeletal rigidity to transcriptional suppression. Pharmacological inhibition of nonmuscle myosin partially rescued lipid accumulation, though not completely, reflecting a trade-off between structural release and longer-term transcriptional commitment. The study extended these analyses to liver, where the researchers observed protection from steatosis in SCoR2-deficient animals. Unlike adipose tissue, hepatocytes did not rely on Myh9 modification. Instead, the authors identified direct S-nitrosylation of ACLY and FASN, confirmed reduced enzymatic activity, and measured diminished fatty acid synthesis. Stable isotope tracing and oxidation assays showed increased fatty acid oxidation, indicating a coordinated shift away from synthesis when denitrosylation was impaired. Liver-specific knockdown experiments demonstrated autonomy of the hepatic effect without altering adiposity, reinforcing tissue-dependent targeting. Throughout, the investigators acknowledged that incomplete cell-type–specific deletion limits resolution of cross-organ coupling, leaving some causal ordering implicit.

To summarize, the new work of Professor Jonathan Stamler and colleagues (known for discovery of S-nitrosylation ) assigns a unifying metabolic role to a denitrosylase previously associated with disparate targets. By linking S-nitrosylation turnover to both transcriptional permissiveness and enzymatic throughput, the findings connect chemical reversibility to physical and metabolic constraints inside lipid-handling cells. The distinction between adipocyte and hepatocyte targets clarifies how a single enzyme can bias storage in one tissue and oxidation in another without invoking separate regulatory logics. The identification of actomyosin rigidity as a gate on adipogenic transcription reframes cytoskeletal dynamics as an active participant in energy storage decisions. Structural flexibility emerges as a prerequisite for sustained lipogenesis, while enforced assembly restricts transcription factor maturation. In hepatocytes, direct modification of synthetic enzymes bypasses transcriptional control entirely, revealing parallel control paths that converge on lipid flux. Human genetic and tissue correlations ground these mechanisms in disease relevance, though the implications remain bounded by context. Interfering with denitrosylation alters lipid handling under dietary stress, yet different pathological settings may engage compensatory nitrosative or oxidative pressures. The tissue specificity observed here cautions against assuming uniform outcomes from systemic modulation. We believe the therapeutic strategies targeting lipid synthesis may benefit from considering eraser enzymes alongside writers. Modulating denitrosylation could redirect carbon flow without forcing global transcriptional shutdown, provided tissue balance is preserved. Whether such modulation remains beneficial across disease states, or requires coordinated targeting of multiple organs, remains an open constraint.

Temporal lobe epilepsy (TLE) is among the most prevalent and disabling focal epilepsies, marked by recurrent spontaneous seizures and enduring cognitive impairments that persist even when seizures are partially controlled. Despite extensive research, available antiepileptic drugs remain largely symptomatic. They suppress seizures without altering the underlying biological processes that drive epileptogenesis, leaving a substantial proportion of patients with drug-resistant disease and progressive cognitive decline. This therapeutic impasse has sharpened interest in identifying cellular and molecular mechanisms that actively contribute to disease progression rather than reflecting downstream injury. Epileptogenesis following an initial insult, such as status epilepticus, unfolds over a prolonged latent period. During this window, a cascade of pathological changes emerges, including neuronal loss, synaptic reorganization, chronic neuroinflammation, and reactive gliosis. These processes are increasingly recognized as dynamic rather than static, suggesting that intervention during this phase may meaningfully alter long-term outcomes. Yet, the field has struggled to identify targets that unify these diverse pathological features into a coherent, actionable framework. Cellular senescence has recently gained attention as a candidate mechanism capable of exerting broad influence on tissue homeostasis. Once viewed primarily as a tumor-suppressive program, senescence is now understood as a metabolically active state characterized by persistent cell-cycle arrest and the secretion of inflammatory mediators collectively known as the senescence-associated secretory phenotype. In peripheral tissues, senescent cells have been shown to distort local microenvironments, amplify inflammation, and impair tissue repair. In the brain, emerging evidence links senescence to aging and neurodegenerative disorders, yet its contribution to epilepsy has remained largely unexplored.

Could senescent cells actively participate in epileptogenesis rather than accumulating as a consequence of repeated seizures? Addressing this question requires direct evidence from human epileptic tissue as well as mechanistic testing in experimental models. To this end, new research work published in Annals of Neurology and conducted by Dr. Tahiyana Khan, Dr. David McFall, Dr. Abbas Hussain, Dr. Logan Frayser, Dr. Timothy Casilli, Dr. Meaghan Steck, Dr. Irene Sanchez‐Brualla, Dr. Noah Kuehn, Dr. Michelle Cho, Dr. Jacqueline Barnes, Dr. Brent Harris, Professor Stefano Vicini, and led by Professor Patrick Forcelli from the Department of Pharmacology and Physiology at Georgetown University, the researchers established cellular senescence as an active, disease-modifying contributor to temporal lobe epilepsy. By integrating human tissue analysis with genetic and pharmacological senolysis in mice, they showed that clearing senescent cells reduces seizures, restores hippocampal plasticity, and rescues spatial memory. The work introduces senescence as a tractable therapeutic target during epileptogenesis rather than a passive marker of injury.

The research team examined of human hippocampal tissue obtained from individuals with medically intractable TLE. Using multiplexed immunofluorescence, the authors detected a marked increase in cells expressing canonical senescence markers compared with autopsy controls. Notably, this elevation was not restricted to a single glial population; senescence markers appeared across microglia, astrocytes, and oligodendrocytes, suggesting a widespread alteration of the glial environment within epileptic hippocampi. The magnitude of this increase exceeded what would be expected from age alone, indicating that epileptic pathology itself strongly promotes senescence. The authors turned to a pilocarpine-induced mouse model of TLE to establish temporal and mechanistic relationships. Senescence markers rose rapidly after status epilepticus, emerging within the latent period and persisting into the chronic phase. Transcript-level analyses and reporter mouse lines confirmed that this phenotype was sustained rather than transient. Although multiple cell types exhibited senescence-associated features, microglia accounted for the largest fraction of senescent cells, prompting further functional analysis of this population. The team performed imaging which showed that senescent microglia displayed consistent alterations in morphology and baseline process motility, consistent with a chronically activated yet functionally constrained state. Importantly, these changes did not simply reflect global microglial activation, as targeted depletion of non-senescent microglia failed to reproduce the observed effects on seizures or cognition. This distinction suggested that senescent microglia represent a functionally distinct subset with disproportionate pathological influence. Moreover, the authors implemented two independent senolytic strategies. In a genetic model permitting selective ablation of p16-expressing cells, partial clearance of senescent cells led to striking outcomes. Treated animals exhibited reduced seizure frequency, improved hippocampal synaptic plasticity, and normalization of spatial memory performance. Remarkably, a subset of animals was entirely protected from developing chronic epilepsy. Parallel experiments using a pharmacological senolytic cocktail achieved comparable reductions in senescent burden and similarly improved behavioral and electrophysiological outcomes.

In conclusion, the research work of Georgetown University scientists demonstrated that senescent cells accumulate in both human TLE and experimental epilepsy, and that their selective removal attenuates seizures and cognitive deficits, the study introduces senescence as a previously unrecognized driver of epileptogenesis. Epilepsy research has long focused on neurons as primary agents of pathology, with glial cells often viewed as secondary responders. The present findings challenge this hierarchy by identifying a small population of senescent glia that disproportionately influences disease trajectory. Despite representing a minority of total cells, these senescent populations appear capable of reshaping the inflammatory and synaptic landscape of the hippocampus in ways that favor seizure persistence and memory dysfunction.

Additionally, the findings suggest that disease modification in epilepsy may be achievable without directly targeting neuronal excitability. Senolytic strategies operate upstream of seizures by altering the cellular environment in which hyperexcitability emerges. This distinction is particularly important for patients with drug-resistant epilepsy, for whom conventional antiseizure medications offer diminishing returns. The partial protection from epilepsy observed in treated animals underscores the possibility that timely intervention during epileptogenesis could prevent the consolidation of chronic disease. The study also highlights the importance of cellular specificity. Broad depletion of microglia failed to improve outcomes, whereas selective elimination of senescent cells proved beneficial. This finding cautions against indiscriminate anti-inflammatory or glial-suppressive approaches and instead supports precision strategies that preserve protective functions while removing pathological subsets. The work has broader relevance to neurological disorders characterized by chronic inflammation and cognitive decline. Senescence has been implicated in neurodegenerative diseases, and the overlap in pathological mechanisms raises the possibility that senolytic therapies could exert cross-disease benefits. However, the study also emphasizes the need for careful translational consideration, as senescence plays complex roles in tissue repair and tumor suppression. In sum, the work of Professor Patrick Forcelli and colleagues opens a new therapeutic avenue with implications that extend well beyond epilepsy itself.

Metastatic breast cancer disease continues to defy even the most aggressive therapeutic strategies. The resilience of these cancers is not simply a matter of genetic mutations; it is deeply rooted in their extraordinary capacity for adaptation. Central to this adaptability is the process known as epithelial-to-mesenchymal transition (EMT). Through EMT, epithelial cancer cells shed their organized, adhesive characteristics and acquire more resilient survival as they transition into a mesenchymal state.  Moreover, and as critical, though often overlooked, is the reverse process, the mesenchymal-to-epithelial transition (MET), which enables these cells to re-establish rapidly growing new colonies. Together, EMT and MET form a fluid and dynamic system of phenotypic shifts that not only drives cancer progression but also undermines the effectiveness of conventional chemo-treatments by making tumor cells far more stress-tolerant.

For years, research efforts have attempted to interrupt this cycle, often by targeting key signaling pathways such as TGF-β, Wnt, and Notch, or by suppressing the expression of master regulators like Snail, Twist, and Zeb1, but with limited success. A major complication is the paradox that arises when EMT is blocked; this often triggers MET, which, rather than halting progression, actually facilitates colonization of drug-resistant cells and tumor regrowth. This frustrating cycle has made it abundantly clear that simply targeting one end of the spectrum is insufficient. What’s needed is a way to disrupt the very foundation that allows cancer cells to shift between these states so fluidly. To this end, a new research paper published in eLife Journal and conducted by Assistant Professor Yi Ban (NYU), Dr. Yue Zou, Dr. Yingzhuo Liu, Ms. Sharrel Lee, Assistant Professor Robert Bednarczyk (University of Chicago), and Associate Professor Dingcheng Gao (Weill Cornell Medicine),  together with Dr. Jianting Sheng, Dr. Yuliang Cao, and Professor Stephen T C Wong (Houston Methodist Hospital), the researchers developed a novel therapeutic strategy for overcoming chemoresistance in breast cancer by targeting ribosome biogenesis (RiBi). Instead of focusing on blocking specific signaling pathways or surface markers, they discovered that the ability of cancer cells to transition between epithelial and mesenchymal states (EMT and MET) critically depends on their capacity to ramp up protein production through enhanced RiBi.

To prove their hypothesis, the researchers turned to the Tri-PyMT EMT lineage-tracing system, which is a sophisticated tool specifically designed to capture how tumor cells shift their identity over time. This model uses an irreversible fluorescence switch, permanently marking cells as they transition from an epithelial state to a mesenchymal one. Interestingly, when the authors cultured these cells under conditions known to promote EMT, they noticed a small fraction of cells lit up with both fluorescent markers simultaneously—these were the so-called “Double+” cells, caught somewhere between their old and new identities. Rather than being a mere curiosity, these cells seemed to represent a critical phase of active change, precisely marking the moment when tumor cells become resistant to therapy. The team isolated these Double+ cells and performed bulk RNA sequencing, finding that genes involved in ribosome biogenesis were highly upregulated. To dig deeper, they turned to single-cell RNA sequencing, hoping for a more granular view. As it turned out, transitional cells consistently showed higher ribosomal gene expression than their fully committed epithelial or mesenchymal counterparts. But correlation alone wasn’t enough. The researchers wanted to know: is this surge in ribosome production vital for the transition to happen? To test this, they used RNA Polymerase I inhibitors—BMH21 and CX5461—to directly block ribosome biogenesis. Remarkably, the transition stalled. Cells treated with these inhibitors clung to their epithelial markers and failed to fully express key mesenchymal proteins like Vimentin and Snail, and vice versa. Genetic knockdown of ribosomal proteins Rps24 and Rps28 produced much the same result, reinforcing the idea that, without the ability to rapidly manufacture new proteins, tumor cells simply couldn’t complete their transformation in either direction. The logical next question was whether this blockade could make tumors more vulnerable to treatment. The research team combined BMH21 with cyclophosphamide, and a striking synergistic effect was observed — the combination was far more lethal to cancer cells than either treatment alone. Encouragingly, this success extended to mouse models, where co-treatment not only reduced overall tumor burden but also suppressed both epithelial and mesenchymal tumor cell populations.

In conclusion, the new study reignited the underlying question of how to weaken one of cancer’s most formidable defenses—its Epithelial-Mesenchymal Plasticity. For years, the field has focused mainly on chasing down specific signaling pathways or suppressing individual molecular markers, with limited long-term success. This research took a different approach. Rather than attacking cancer cells at the surface level, the investigators turned their attention to a fundamental process that underpins the entire phenomenon of state switching: ribosome biogenesis. In doing so, they uncovered a critical dependency that had gone largely unnoticed. Cancer cells, it turns out, can’t easily shift between epithelial and mesenchymal identities without first ramping up their capacity to produce new proteins. This isn’t just a biochemical side note—it’s a core requirement for executing the extensive molecular and structural remodeling these transitions demand.

The broader implications of these findings are hard to ignore. Most notably, this work offers a strong rationale for combining ribosome biogenesis inhibitors with conventional chemotherapy, not to replace existing treatments, but to strategically weaken cancer cells exactly when they’re at their most vulnerable—during the exhausting process of phenotypic transition. By hitting them at this critical juncture, the chances of preventing or at least delaying the emergence of highly drug-resistant populations are dramatically increased.

Another key finding of the authors’ work is the importance of treatment timing and the discovery that RiBi activity rises only briefly during EMT and MET highlights a narrow but potentially powerful therapeutic window. Instead of applying treatments uniformly, as is so often the case, this suggests that carefully timed interventions could more effectively disrupt the plasticity that allows cancer cells to adapt and survive. However, the timing of catching the peak of the transitioning cells during treatment requires further investigation. In many ways, this reframes treatment scheduling from a matter of convenience to a critical tactical decision. Perhaps equally important, the authors raise the intriguing possibility that ribosome biogenesis itself could serve as a prognostic marker. Patients with tumors exhibiting high RiBi activity might be precisely the individuals most likely to benefit from this combinatorial approach. Stepping back, what this research really challenges is the long-held belief that it’s enough to target cancer cells in one state or another. Instead, it points to a more disruptive—and arguably more effective—strategy: stripping cancer cells of their ability to switch identities altogether.

Computed tomography (CT) has revolutionized diagnostic medicine, providing fast, high-resolution imaging that supports the detection and management of countless diseases. From trauma evaluations in emergency departments to cancer staging in oncology clinics, CT is now a routine fixture in clinical practice. In 2023 alone, an estimated 93 million CT scans were performed in the United States, involving over 61 million patients. This widespread use has unquestionably enhanced clinical decision-making, enabling early diagnoses and improved outcomes across various medical specialties. However, the increasing reliance on CT has also raised concerns about the cumulative exposure of patients to ionizing radiation—a known carcinogen—especially given that many scans deliver radiation doses significantly higher than those associated with standard radiographs. The paradox of CT imaging lies in its dual nature: it is both a diagnostic marvel and a potential public health hazard. Ionizing radiation, particularly when used frequently or at high doses, can damage DNA and increase the risk of malignancies over a patient’s lifetime. While this risk is relatively small on a per-scan basis, the sheer volume of CT imaging performed nationally magnifies the public health implications. Notably, cancer risks are not uniformly distributed across populations. Children are particularly vulnerable due to their longer post-exposure life expectancy and greater sensitivity of developing tissues. Yet, adults account for the majority of cumulative radiation burden simply because they undergo the most imaging.

Historically, efforts to quantify CT-associated cancer risk have been limited by incomplete data, generalizations about patient anatomy, and coarse approximations of radiation doses. A pivotal 2009 study led by Berrington de González provided the first comprehensive projection, estimating that CT use in 2007 could result in 29,000 future cancers. That estimate, although groundbreaking at the time, was based on national imaging averages and dose assumptions derived from relatively outdated technology. In the years since, CT technology and utilization patterns have evolved substantially. Multiphasic imaging, for instance, which entails multiple scans in a single session, is now more common, and it significantly increases radiation exposure. Despite the availability of dose-reduction techniques, such as iterative reconstruction algorithms and automatic exposure control, their adoption remains inconsistent across health care systems.

These trends raised a critical question: how much cancer risk are we incurring under the current landscape of CT imaging? More specifically, how do age, sex, anatomical region imaged, and scan parameters contribute to that risk at the national scale today? The lack of up-to-date, granular data linking real-world CT practices to projected cancer outcomes created a knowledge gap with significant implications for both clinical practice and public health policy.

To this account, Professor Rebecca Smith-Bindman from the University of California, San Francisco and her team undertook a rigorous, methodologically sophisticated study to update and refine national projections of lifetime cancer risk associated with CT scans performed in 2023. Their work, published in JAMA Internal Medicine, leverages individual-level scan data from the UCSF International CT Dose Registry, which includes over 120,000 CT exams from diverse U.S. hospitals and imaging centers. Unlike previous assessments, this study does not rely on assumed dose distributions. Instead, it incorporates examination-specific acquisition parameters—such as scan length, tube current, and patient size—to simulate absorbed radiation doses in 18 organs using Monte Carlo radiation transport modeling. These doses are then paired with state-of-the-art risk modeling tools, including the National Cancer Institute’s RadRAT software, to generate lifetime cancer risk projections.

To investigate the cancer risk associated with modern CT imaging practices in the United States, the research team led by Professor Rebecca Smith-Bindman designed a study that integrated large-scale real-world imaging data with high-resolution dosimetry and advanced cancer risk modeling. Their approach was both methodologically rigorous and deeply grounded in clinical realities, reflecting a clear effort to bridge epidemiological insight with the granular details of radiological practice. Rather than relying on outdated assumptions or generalized scan categories, the team assembled a patient-level dataset drawn from the UCSF International CT Dose Registry, which includes scans performed across 143 hospitals and outpatient centers in 20 U.S. states. In total, this registry captured more than 120,000 CT exams, each tagged with detailed metadata such as patient age, sex, body region scanned, scan length, kilovoltage, milliamperage, and more.

What set this study apart was its precision in reconstructing the radiation dose absorbed by specific organs for each type of CT exam. Using Monte Carlo simulations (specifically, the MCNPX code), the team modeled radiation transport through anatomically realistic digital phantoms representing various ages and body types. This allowed them to compute absorbed doses for 18 distinct organs, taking into account real-world scan parameters rather than idealized ones. They found, for example, that abdomen and pelvis CT scans delivered some of the highest doses, particularly when performed with multiphase protocols, which are often unnecessary yet still commonly used. In contrast, extremity CT scans resulted in minimal organ exposure, highlighting how radiation risks vary significantly depending on the scan type.

Armed with these organ-specific dose estimates, the researchers moved to the next phase: estimating lifetime cancer risks. For this, they employed the National Cancer Institute’s RadRAT software, which uses risk models largely based on data from the Life Span Study of atomic bomb survivors, but updated and tailored to modern U.S. demographics. Importantly, the software factors in baseline cancer rates by age and sex, as well as mortality risks unrelated to cancer, providing a probabilistic output rather than a deterministic one. Applying RadRAT across the stratified dataset—418 unique combinations of patient age, sex, and CT exam type—the team generated cancer risk estimates for the entire U.S. population exposed to CT scans in 2023. The findings were sobering: roughly 103,000 future cancers were projected to arise from the 93 million CT scans performed that year. What made these projections especially compelling was the researchers’ ability to dissect them by subgroups. Although children had the highest per-scan risk due to their developing tissues and longer life expectancy, adults contributed over 90% of the projected cancers simply because they underwent the vast majority of CT scans. Lung cancer emerged as the most common outcome, with an estimated 22,400 cases attributed to radiation exposure, followed by colon cancer, leukemia, and bladder cancer. In women, breast and thyroid cancers also appeared prominently in the projections. Interestingly, head CTs were the leading cause of radiation-induced cancers in children, whereas abdomen and pelvis CTs were the dominant contributor in adults.

Moreover, the authors ran a battery of sensitivity analyses to test the robustness of their projections under different assumptions. For instance, when organ doses were varied by ±20%, the total number of projected cancers ranged from roughly 80,000 to 127,000—still substantial, even at the lower end. They also examined how results shifted if more or fewer CTs were performed on pediatric patients or if multiphase imaging was excluded. Notably, even under the most conservative modeling assumptions, the projected cancer burden remained high, reinforcing the urgency of the issue. Another revealing insight came from their analysis of CT use at the end of life. Since radiation-induced cancers take years to manifest, scans performed in the final year of life were excluded from risk calculations. By analyzing data from Kaiser Permanente Northern California, the team estimated that 10.6% of all CTs fell into this category and were unlikely to result in future cancers. Removing these from the risk pool gave a more accurate picture of long-term cancer incidence. It also suggested that a nontrivial portion of imaging might be used in contexts where the long-term risk is irrelevant, further emphasizing the need to differentiate between justified and potentially excessive use.

What became clear from these experiments and their resulting data is that radiation exposure from CT scans is not a hypothetical concern—it is a quantifiable, population-wide risk that demands greater attention. The researchers found that CT could account for up to 5% of all new cancer cases annually if current practices persist, putting it on par with other major modifiable risk factors like alcohol and obesity. And yet, unlike lifestyle choices, radiation exposure from imaging is externally administered and, in many cases, potentially avoidable or reducible through better scanning practices, protocol standardization, and stronger justification requirements.

The significance of this UCSF clinical study is in its ability to quantify, with unprecedented precision, the hidden long-term risks embedded in one of modern medicine’s most frequently used technologies. While  CT scans have become essential for diagnostic clarity, the research by Smith-Bindman and her team reveals that the cumulative consequence of this widespread imaging practice may be far more substantial than previously recognized. By using real-world data and detailed dose modeling for individual organs across diverse patient groups, the study not only updates prior estimates—it reframes the discussion entirely. What makes the findings so impactful is that they are not abstract predictions, but grounded projections based on actual scan parameters, patient demographics, and modern imaging frequencies. The estimate that CT imaging performed in just one year—2023—may result in over 100,000 future cancers gives new urgency to a conversation that has, until now, remained largely within the realm of theoretical concern. The implications are clear: the medical community must treat radiation exposure from diagnostic imaging with the same seriousness it affords other preventable health risks. One of the most striking implications is the sheer scale of risk created by standard clinical operations. These are not edge cases or experimental exposures but routine scans administered daily across the country. If nothing changes, CT use alone could account for approximately 5% of all new cancer diagnoses annually—a proportion comparable to other major modifiable risk factors. Unlike tobacco or diet, however, this risk is largely imposed rather than chosen, and therefore places an even greater ethical obligation on health systems to mitigate harm.

Clinically, the new study highlights the need for rigorous justification before ordering any CT scan, particularly when alternative imaging modalities like MRI or ultrasound could suffice. It also calls for immediate re-evaluation of multiphase scanning practices, which significantly increase dose but are often used reflexively, without clear added value. The research further highlights the importance of tailoring scan protocols to patient-specific factors—such as age, size, and clinical indication—to minimize unnecessary radiation exposure. On a policy level, the findings strengthen the argument for national radiation dose benchmarking and mandatory reporting, particularly for institutions that lag in adopting dose-reduction technologies. The study also supports broader implementation of decision-support tools that guide clinicians in selecting the most appropriate imaging study for each case. Insurance providers and regulatory agencies may find in this data a strong rationale for incentivizing low-dose practices and penalizing unjustified or excessive scanning.

Psychiatric disorders are among the most challenging medical conditions to understand and treat. They affect millions worldwide, yet their underlying causes remain elusive. Unlike many physical illnesses, which can often be traced to a single gene mutation or environmental factor, psychiatric conditions are highly polygenic (they are influenced by numerous genetic variations acting in concert). Moreover, these disorders frequently co-occur, with individuals diagnosed with one condition often exhibiting symptoms of others. This phenomenon, known as pleiotropy, suggests a shared genetic architecture that underlies multiple psychiatric conditions. However, the precise molecular mechanisms driving this overlap remain largely unknown, presenting a significant challenge for researchers and clinicians alike. The rise of genome-wide association studies (GWAS) has led to the identification of hundreds of genetic variants associated with psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, Tourette syndrome, and anorexia nervosa. While these studies have been instrumental in pinpointing statistical associations, they do not provide insights into the biological function of these variants. Identifying a genetic risk factor is only the first step—understanding how it influences gene expression, cellular function, and ultimately behavior is far more complex. Many of these risk variants are located in non-coding regions of the genome, which means they do not directly alter protein structure but instead likely function as regulatory elements that influence when and where genes are expressed. This raises critical questions: Which genes are being regulated? How do these variants contribute to disease risk? And why do some variants influence multiple disorders while others appear disorder-specific? Addressing these questions requires functional genomics approaches that go beyond statistical associations. The lack of direct experimental validation for many psychiatric risk variants has left researchers with uncertainty about their biological relevance. Moreover, given that psychiatric disorders arise from disruptions in neurodevelopment and brain circuitry, studying genetic risk factors in the appropriate cellular context—such as neurons—remains an ongoing challenge. Traditional methods of studying gene regulation, such as reporter assays or chromatin immunoprecipitation, have been limited in scale and resolution, preventing a comprehensive analysis of the thousands of variants linked to psychiatric disorders.

To overcome these barriers, new research paper published in Cell Journal and conducted by Dr. Sool Lee, Dr. Jessica McAfee, Dr. Jiseok Lee, Dr. Alejandro Gomez, Dr. Austin Ledford, Dr. Declan Clarke, Hyunggyu Min, Professor Mark Gerstein, Professor Alan Boyle, Professor  Patrick Sullivan, Professor  Adriana Beltran, and Professor Hyejung Won from the University of North Carolina at Chapel Hill and Yale University used a massively parallel reporter assay (MPRA) which is high-throughput experimental technique to allow for the simultaneous testing of thousands of genetic variants to determine their impact on gene expression regulation. By performing MPRA in human neural progenitor cells (HNPs), the researchers identified which genetic variants have functional regulatory activity and to distinguish between those with pleiotropic effects (influencing multiple disorders) and those with disorder-specific effects.  Unlike conventional methods that examine one variant at a time, MPRA allows scientists to test thousands simultaneously, providing a clearer picture of how these variants influence gene expression. To ensure relevance to brain development and psychiatric disorders, the authors introduced these genetic sequences into HNPs, an early-stage cell type that gives rise to neurons. After introducing the DNA sequences containing risk variants, they measured RNA output, a direct readout of whether a particular variant could enhance or suppress gene activity. This experiment revealed that about 9.3% of the tested variants exhibited significant regulatory activity, confirming that a subset of psychiatric risk variants do not merely correlate with disease but likely play a direct role in gene expression changes during brain development. As they analyzed these regulatory variants, an interesting pattern emerged: variants associated with multiple psychiatric disorders (pleiotropic variants) displayed a broader impact on gene regulation than disorder-specific variants. These pleiotropic variants exhibited chromatin accessibility—an indicator of active gene regulation—across multiple cell types in the neuronal lineage, whereas disorder-specific variants had a more restricted impact. This suggested that pleiotropic variants may contribute to psychiatric disease by influencing gene networks that are active in a wide range of developing brain cells, whereas disorder-specific variants may exert their effects in more specialized cell populations. Further analysis revealed that these pleiotropic variants often altered transcription factor binding motifs, the DNA sequences where proteins that regulate gene expression attach. Importantly, the affected transcription factors were highly connected in protein-protein interaction networks, suggesting that they play central roles in gene regulation and may propagate their effects through multiple biological pathways.

To confirm that these genetic variants had real biological effects in living cells, the team turned to CRISPR-based gene perturbation, specifically a high-throughput method known as CROP-seq. By using CRISPR interference (CRISPRi), they selectively disrupted specific variants in human-induced pluripotent stem cell (hiPSC)-derived neurons and then measured which genes were affected. Their first target, rs301804, had been identified through MPRA as an active regulatory variant. When they perturbed this variant, it led to significant downregulation of RERE, a gene involved in neurodevelopment and previously linked to cognitive and psychiatric disorders. This confirmed that rs301804 directly regulates RERE, rather than merely being statistically associated with it. Similarly, another highly pleiotropic variant, rs4513167, was linked to DCC, a gene that guides neuronal growth during brain development. Disrupting this variant caused a drop in DCC expression, reinforcing its functional role. This was a key finding—many GWAS studies assume that the closest gene to a variant is its target, but these experiments demonstrated that variants often regulate genes located far away, necessitating functional testing rather than assumptions. Moreover, the researchers compared mutation intolerance scores of the genes affected by these regulatory variants. Genes associated with pleiotropic variants were significantly more constrained, meaning they are rarely disrupted by mutations in the general population, likely because they are essential for brain development. This contrasted with disorder-specific genes, which showed less evolutionary constraint, suggesting that their functions may be more specialized and dispensable in some contexts. Further, pleiotropic genes were more highly connected in protein protein interaction networks, meaning they interact with many other proteins, reinforcing their role as central regulators of gene function. Furthermore, the researchers also wanted to determine whether pleiotropic variants influenced gene expression at different stages of brain development. By analyzing chromatin accessibility data, they found that these variants were active across a broad range of neuronal subtypes, particularly upper-layer excitatory neurons, which are crucial for brain connectivity. In contrast, disorder-specific variants had more localized effects, often restricted to a single developmental stage or neuronal subtype. This distinction could explain why some psychiatric disorders share genetic risk factors while others have more distinct genetic profiles. To further test the functional relevance of their findings, the team conducted in vivo CRISPR perturbation experiments in mouse brains. They targeted Anp32e, a pleiotropic gene, and Kmt5a, a disorder-specific gene, to compare their downstream effects. When they disrupted Anp32e, it led to widespread changes in neuronal gene expression, affecting multiple cell types and altering networks involved in synaptic function. By contrast, disrupting Kmt5a led to more localized changes, primarily in glial cells, supporting their earlier observations that pleiotropic genes exert broader regulatory influence while disorder-specific genes act more selectively. One of the most compelling aspects of this study was how it linked common genetic variants with rare disease-associated mutations. The authors found that genes affected by common pleiotropic variants overlapped significantly with genes known to carry rare, protein-disrupting mutations in neurodevelopmental disorders like autism and developmental delay. This reinforces the idea that common and rare genetic variation may converge on the same biological pathways, providing multiple routes to psychiatric disease.

In conclusion, the research work of University of North Carolina at Chapel Hill scientists and their collaborators successfully provided direct experimental evidence of how variants function at the molecular level. The use of MPRA combined with CRISPR-based perturbation allowed the researchers to pinpoint which genetic variants influence gene regulation, which genes they control, and how they contribute to multiple psychiatric disorders. This is a crucial step in bridging the gap between genetics and neurobiology, offering a clearer understanding of the molecular underpinnings of mental illnesses. We think an important finding is the realization that pleiotropic genetic variants—those linked to multiple psychiatric disorders—exert their influence across a broader range of neuronal cell types than disorder-specific variants. This suggests that these shared risk factors may disrupt fundamental neurodevelopmental processes that are common across multiple conditions, explaining why psychiatric disorders often co-occur. The discovery that pleiotropic variants target genes with high mutational constraint further emphasizes their biological importance, as these genes appear to be essential for normal brain function. This could inform new drug discovery efforts, as targeting these key regulatory pathways may have therapeutic potential for multiple psychiatric conditions rather than just one. Perhaps most importantly, the findings open the door for precision medicine in psychiatry. If psychiatric disorders share common genetic mechanisms, treatments could be developed that target the underlying biology rather than just the symptoms. For example, drugs that modulate transcription factor networks or chromatin accessibility could have broad therapeutic effects across multiple psychiatric conditions. Additionally, this study provides a framework for identifying which patients might respond best to certain treatments based on their genetic profile, paving the way for more personalized interventions.

The relationship between autophagy, the unfolded protein response (UPR), and cancer is a fascinating area of research, especially when you think about how these processes keep cells functioning under stress. Cancer cells are under constant pressure because they multiply so quickly, pushing their cellular machinery—like the endoplasmic reticulum (ER)—to the brink. This kind of stress leads to a buildup of misfolded proteins, which then activates the UPR. The UPR is basically the cell’s way of dealing with this chaos, trying to restore balance or, if that fails, signaling the cell to self-destruct. Interestingly, while the UPR generally helps cells survive tough conditions, in cancer cells, it can be a weak spot that scientists are eager to target for treatments. Among the UPR’s three main branches, ATF6 (activating transcription factor 6) has drawn attention as an underexplored player, especially because of its role in regulating lysosomes and autophagy. Autophagy is like the cell’s cleanup crew, it breaks down and recycle unwanted materials to maintain balance. Cancer cells, being the opportunists they are, hijack this process to survive the harsh environments they create. Two major types of autophagy—macroautophagy and chaperone-mediated autophagy (CMA)—both rely on lysosomes, which are essentially the cell’s waste disposal units. These lysosomes need to function properly for autophagy to work, but we still do not know enough about how they are kept in good shape, especially under ER stress. ATF6 seems to play a big role here which make it an exciting focus for deeper investigation. One of the biggest challenges in cancer research is figuring out how to handle mutant TP53 (MUT TP53), a gene mutation found in many cancers. Normally, TP53 acts as a tumor suppressor, but when mutated, it not only loses this ability but also gains harmful properties that help tumors grow and resist treatment. Recent studies have hinted that lysosomes rather than proteasomes are key to breaking down MUT TP53. However, the exact mechanisms and how the UPR influences this process are still unclear. In a new study published in Autophagy Journal and conducted by Rossella Benedetti, Maria Anele Romeo, Andrea Arena, Maria Saveria Gilardini Montani, & Dr. Mara Cirone from Sapienza” University of Rome alongside Gabriella D’Orazi from the University “G. D’Annunzio” in Italy investigated how ATF6 supports lysosomal function during ER stress and affects MUT TP53 degradation. Their findings are critical for designing therapies, as targeting autophagy or UPR pathways could unintentionally stabilize MUT TP53, potentially doing more harm than good.

The research team started by testing two well-known ER stressors, thapsigargin (TG) and tunicamycin (TN), on colon cancer cell lines carrying common TP53 mutations. These stressors are known to activate the UPR. After treating the cells, they noticed a significant drop in the levels of MUT TP53 protein, suggesting that ER stress plays a role in breaking it down. To figure out how this happens, the researchers blocked each of the three UPR pathways individually. They discovered that only when ATF6 was inhibited did MUT TP53 levels stop decreasing, highlighting ATF6’s importance in this process. Moreover, the authors found that lysosomal activity, not proteasomal pathways, was central to clearing MUT TP53 and they confirmed this by using ammonium chloride which disrupts lysosome function. When they treated cells with TG and ammonium chloride together, the degradation of MUT TP53 was halted. Further tests using fluorescent dyes to measure lysosomal acidity revealed that ATF6 inhibition reduced the acidity of lysosomes. Since acidity is critical for their function, this showed that ATF6 helps lysosomes work properly during ER stress, allowing MUT TP53 to be degraded. To explore how autophagy contributes, the team focused on two pathways: macroautophagy and CMA. By silencing genes essential to these processes—ATG5 for macroautophagy and LAMP2A for CMA—they demonstrated that both played roles in degrading MUT TP53 during TN treatment. However, during TG treatment, macroautophagy was suppressed, leaving CMA as the dominant pathway for breaking down MUT TP53. This revealed how cancer cells adapt to stress by using different autophagic mechanisms based on the situation. One of the study’s key findings was the effect of ATF6 inhibition on lysosomal regulators. Western blot analysis showed that blocking ATF6 led to a decrease in TFEB, a master regulator of lysosome function. At the same time, mTOR, a kinase that suppresses autophagy, became more active. These changes created a feedback loop where lysosomal dysfunction stabilized MUT TP53, further disrupting autophagic processes. In cells with MUT TP53, this vicious cycle could make cancer cells even harder to treat. Furthermore, the researchers demonstrated how ATF6 directly supports lysosomal health. Overexpressing a cleaved form of ATF6 improved lysosomal function and sped up MUT TP53 breakdown, while silencing ATF6 had the opposite effect. Immunofluorescence imaging confirmed that MUT TP53 localized to lysosomes in TG-treated cells, providing clear visual evidence of its lysosomal degradation pathway.

In conclusion, the Italian scientists revealed the complex relationship between ATF6, lysosomal function, and autophagy in cancer, especially when it comes to breaking down MUT TP53. Moreover, the authors highlighted that while ATF6 inhibitors might initially seem like a good way to disrupt cancer cell survival, their findings also showed blocking ATF6 could stabilize MUT TP53 and by this potentially activate pathways that help tumors survive. This paradoxical effect could undermine the very treatments meant to kill the cancer. As a result, any therapy targeting ATF6 needs to be carefully adapted to the tumor’s genetic makeup, especially regarding its TP53 mutation status. The dual role of autophagy in cancer is another important point raised. On one hand, autophagy helps cancer cells survive by cleaning up cellular debris during stress. On the other, it can be used to break down harmful proteins like MUT TP53. By uncovering how macroautophagy and CMA contribute to this process, the study opens the door for more precise therapies. For example, enhancing CMA in specific cases might lower MUT TP53 levels without accidentally helping the tumor in other ways. Additionally, the role of ATF6 in balancing these outcomes teach us the need for therapies that hit the right targets without unintentionally aiding cancer survival.

Goldenhar syndrome, sometimes referred to as oculo-auriculo-vertebral spectrum, is a rare condition that significantly affects how the face and skull develop. People with this syndrome often have abnormalities in the first and second pharyngeal arches, which can result in features like underdeveloped jaws, small or missing ears, and occasionally issues with their spine. Although this condition has been known about for many years, scientists still do not fully understand the genetic and molecular reasons behind it. A major difficulty in studying Goldenhar syndrome is how differently it can appear in different people. Some individuals might have only mild features, while others experience severe deformities. This wide range of symptoms makes it hard for researchers to pinpoint consistent genetic causes. Adding to the complexity, even within families, not everyone who inherits a genetic mutation shows the same symptoms. Scientists have identified a few genes, like MYT1 and FOXI3, that are linked to the condition, but these explain only a small percentage of cases. For most people with Goldenhar syndrome, the underlying genetic or molecular causes remain unknown. This leaves families with limited answers and makes it harder for doctors to offer clear diagnoses.

To address these challenges, new study published in Annals of the New York Academy of Sciences and conducted by Dr. Xiaomin Niu, medical student Fuyu Zhang, Wei Gu, Bo Zhang, and led by Professor Xiaowei Chen from the Chinese Academy of Medical Sciences & Peking Union Medical College investigated the role of a protein called Fibulin-2 (FBLN2). This protein, found in the extracellular matrix, is thought to play an important part in the development of cranial neural crest cells (CNCCs). These cells are essential for forming bones, cartilage, and connective tissue in the head and neck. If CNCCs do not properly migrate, grow, or mature, craniofacial anomalies can result, making them key to understanding conditions like Goldenhar syndrome. The researchers started by looking at a five-generation family tree with multiple members affected by the condition. They used whole-exome sequencing to search for rare genetic variants that might be linked to the syndrome. Through an advanced method called rare variant non-parametric linkage analysis, they zeroed in on FBLN2 as a possible culprit. The identified mutation, a missense variant, altered a key amino acid in the calcium-binding region of the Fibulin-2 protein. Using computational tools, they predicted that this change could seriously affect how the protein is shaped and how it functions, giving an important clue about its role in the syndrome. To confirm their findings, the team used zebrafish, which are a popular model for studying craniofacial development because their genetics and development are similar to humans in many ways. Using CRISPR/Cas9 gene-editing, they created a zebrafish line that lacked the fbln2 gene. When they examined the fish, they found noticeable craniofacial defects, such as malformed cartilage in the jaw and poorly organized chondrocytes. While normal zebrafish showed neat stacks of well-structured chondrocytes, the mutants had cells that were misshapen and misaligned. This clearly showed that FBLN2 plays a vital role in keeping craniofacial cartilage properly structured. The authors then wanted to understand better the molecular reasons behind these abnormalities. They analyzed markers involved in CNCC development and in the zebrafish missing fbln2, markers like sox9a and col2a1a, which are essential for chondrocyte differentiation, were significantly reduced. This demonstrated that without fbln2, CNCCs struggled to mature into functional chondrocytes and disrupted cartilage formation. They also explored whether fbln2 affected cell behavior, like growth and programmed cell death. By staining for dividing and dying cells, they found more apoptosis (cell death) and less proliferation (growth) in the CNCCs of mutant fish. These imbalances likely contributed to the severe craniofacial abnormalities observed, highlighting the importance of FBLN2 in CNCC survival and function. Finally, the team examined the BMP signaling pathway, a key regulator of CNCC development. In the mutants, they observed significantly lower activation of this pathway, particularly in the pharyngeal arches. This suggested that losing fbln2 disrupted BMP signaling, which is essential for guiding CNCCs in craniofacial development. Linking FBLN2 to this pathway revealed a critical mechanism behind the observed defects.

In conclusion, professor Xiaowei Chen and her team have made a significant advancement in our understanding Goldenhar syndrome and showed how the gene FBLN2 plays a key role in craniofacial development. Their research sheds light on the complex genetic and molecular mechanisms behind this rare condition, offering much-needed clarity for a disorder that has long puzzled scientists and clinicians. One of the most exciting implications of this work is how it could improve genetic testing. Now that FBLN2 has been highlighted as an important factor, clinicians might include it in genetic panels for craniofacial anomalies. This would allow earlier and more accurate diagnoses, particularly for families with a history of craniofacial disorders. It could also make genetic counseling and even prenatal diagnosis more precise, giving families clearer answers and better options moving forward. On the treatment front, the findings could lead to innovative therapies. Since the researchers linked FBLN2 mutations to problems in BMP signaling, they have pointed to a pathway that might be adjusted to help affected individuals. Targeting BMP signaling with drugs or biologics could potentially prevent or even correct some craniofacial defects. Additionally, the study underscores the importance of Fibulin-2 in the extracellular matrix, suggesting that therapies designed to restore this structural integrity might also prove beneficial. The impact of this research goes beyond Goldenhar syndrome. Fibulin-2’s role in CNCCs hints that it may be involved in other conditions linked to neural crest dysfunction, such as Treacher Collins syndrome. This discovery provides a framework for studying genetic and molecular pathways shared across multiple disorders, paving the way for broader applications.

Glycosylation, the process of attaching sugar molecules to proteins or lipids is a key biological mechanism that impacts countless cellular processes from immune responses to cell communication and even the clearance of proteins from the bloodstream. However, despite its importance, we still do not fully understand how this complex process works and there are many unanswered questions about how specific glycan structures—complex sugar chains—are created and how they influence various biological systems. Among these structures, LacdiNAc (GalNAcβ1-4GlcNAc) is especially intriguing because of its distinct roles in regulating protein behavior. It has been linked to critical processes like stem cell maintenance, bone health, and the turnover of glycoproteins. LacdiNAc is synthesized by two enzymes, B4GALNT3 and B4GALNT4, which modify specific glycan structures on proteins. While the more common LacNAc (Galβ1-4GlcNAc) is often used as a base for terminal modifications like sialylation or fucosylation, LacdiNAc serves different purposes. For instance, it can control how quickly proteins are cleared from the bloodstream or help maintain the stemness of certain cells. Despite its significance, researchers have struggled to fully understand how LacdiNAc is synthesized and why it only appears on specific proteins. Another challenge is understanding how B4GALNT3 and B4GALNT4 work at a molecular level. Scientists are still trying to uncover how these enzymes recognize their substrates and what structural features allow them to function. Another puzzle involves how LacdiNAc affects other glycan modifications, such as the addition of sialic acid or fucose, and how it interacts with bisecting GlcNAc—a modification that seems to inhibit LacdiNAc formation, and vice versa.

To address these challenges, a new study published in the Journal of Biological Chemistry led by Professor Yasuhiko Kizuka and Yuko Tokoro from Gifu University together with Dr. Masamichi Nagae from Osaka University, Dr. Miyako Nakano from Hiroshima University and Dr. Anne Harduin-Lepers from University of Lille, shed light on these issues and focused on B4GALNT3. The research team began by using structural modeling with AlphaFold2 to analyze the enzyme B4GALNT3 and found that B4GALNT3 has a special PA14 domain, a region that does not directly catalyze reactions but is likely crucial for recognizing glycans and helping the enzyme function properly. To test this theory, the team created a mutant version of B4GALNT3 that lacked the PA14 domain and then expressed this mutant in HEK293 cells. What they observed was striking—the mutant enzyme showed a dramatic drop in activity compared to the normal version, both in live cells and in lab-based experiments. Interestingly, the mutant enzyme still folded correctly and was located in the right part of the cell, which ruled out structural instability as the cause. This finding made it clear that the PA14 domain plays an essential role in helping the enzyme do its job by stabilizing the active site and enabling key glycan modifications.

The authors wanted to go further and understand how B4GALNT3 works on different substrates. They tested the enzyme’s ability to produce LacdiNAc on a variety of molecules, including N-glycans, O-GalNAc glycans, and glycoproteins. By using advanced biochemical assays and reverse-phase HPLC to analyze reaction products, they found that the normal enzyme efficiently modified these substrates, while the mutant enzyme with no PA14 domain was almost completely inactive. This provided strong evidence that the PA14 domain is not just important but absolutely necessary for B4GALNT3 to function. The team also looked at how LacdiNAc synthesis influences other glycan modifications. They found that when LacdiNAc was present, it inhibited several downstream processes like sialylation, fucosylation, and the synthesis of the HNK-1 epitope. For instance, enzymes such as ST6GAL1 and FUT2, which are involved in adding terminal modifications, were less effective when LacdiNAc was part of the substrate. Through careful in vitro experiments, the researchers confirmed that LacdiNAc alters how enzymes interact with substrates, effectively shaping the overall glycosylation pattern of glycoproteins. The researchers also explored how LacdiNAc interacts with another glycan modification called bisecting GlcNAc, which is added by GnT-III and discovered a reciprocal relationship: bisecting GlcNAc prevented the formation of LacdiNAc, and LacdiNAc partially blocked GnT-III activity. This interaction highlighted the complex regulatory network of glycosylation, showing how different modifications can influence one another.

In conclusion, the new study, led by Professor Yasuhiko Kizuka and colleagues, offered better understanding of glycosylation, with special focus on the creation and regulatory role of LacdiNAc. The practical implications of this research are exciting. For instance, LacdiNAc’s ability to regulate how long proteins stay active in the bloodstream has clear potential for therapeutic applications. Moreover, adding LacdiNAc to therapeutic proteins could help fine-tune their activity or reduce unwanted immune responses. Alternatively, blocking the activity of B4GALNT3 could extend the half-life of certain proteins which make them more effective as treatments. The authors’ findings also have new applications for bone health because with the examination on how LacdiNAc affects proteins like sclerostin which regulates bone mass, the authors has paved the way for potential new treatments for osteoporosis and other bone-related conditions. Furthermore, the link between LacdiNAc and stem cell behavior opens doors for regenerative medicine and cancer therapies, especially in cancers where altered glycan structures play a role in tumor growth and spread. According to the authors and from a structural biology perspective, the role of the PA14 domain in glycosylation deserves further exploration because understanding how it works at a three-dimensional level could lead to advances in enzyme design which will help researchers develop targeted inhibitors or engineered enzymes for medical and research purposes.